Cookies auf der KCI-Website
Wir verwenden Cookies, um Ihnen die Nutzung unserer Website zu erleichtern. Weitere Informationen zu Cookies und deren Verwendung erhalten Sie hier Privacy Policy. Um Ihnen das Navigieren zu erleichtern, empfehlen wir Ihnen, die Cookies zu akzeptieren.
Eingabehilfen | Sitemap | Kontaktieren Sie uns | Service-Hotline 0800/7833524
Deutschland Change Country
Startseite  |  Einsatzgebiete  |  Produkte  |  Klinische Evidenz  |  Fortbildung & Training  |  Für Patienten  |  Kundendienst
Sie sind hier Startseite > Nachrichten & Medien > Published Literature Review Demonstrates Promise of V.A.C. VeraFlo™ Therapy in Wound Treatment
Drucken

Published Literature Review Demonstrates Promise of V.A.C. VeraFlo™ Therapy in Wound Treatment

Freigegeben : 20 Juli 2015
KCI, Leader in Advanced Wound Care Solutions

SAN ANTONIO, July 20, 2015 — Acelity, a global wound care and regenerative medicine company, is pleased to announce that a recent peer-reviewed publication in International Wound Journal supports the use of negative pressure wound therapy with intermittent instillation and dwell time (NPWTi-d; V.A.C. VeraFlo Therapy) in the treatment of acute and chronic wounds. In this publication, the authors noted the use of V.A.C. VeraFlo Therapy as a first-line therapy in a wide subset of complex wounds. The authors also proposed a clinical approach for appropriate application of NPWTi-d which is supported with a case series demonstrating successful use.

“Our findings suggest that with patient optimization and proper debridement, V.A.C. VeraFlo Therapy is an important part of an active wound closure strategy,” said first author Subhas Gupta, MD, CM, PhD, FRCSC, FACS, Department of Plastic Surgery, Loma Linda University School of Medicine, California. “I look forward to reviewing the results of clinical data Acelity is currently collecting to better characterize the role this promising therapy can play in providing the best approach for wound treatment.”

Negative pressure wound therapy is a well-established advanced therapy, and the introduction of automated volumetric delivery of topical wound solutions with an adjustable dwell time in combination with NPWT has been shown to demonstrate clinical and economic benefits in wound healing. V.A.C. VeraFlo Therapy is the only system that offers intermittent instillation with dwell.

“This study emphasizes the importance of advanced wound therapies such as V.A.C. VeraFlo Therapy in helping clinicians more efficiently and accurately treat their patients,” said Ron Silverman, M.D., Chief Medical Officer, Acelity. “As a leader in negative pressure wound therapy, we are committed to investing in the collection of clinical data, and look forward to additional research evaluating the value and efficacy of topical wound solution delivery with dwell in combination with NPWT through V.A.C. VeraFlo Therapy.”

To view the complete publication, “Clinical Recommendations and Practical Guide for Negative Pressure Wound Therapy with Instillation” by Subhas Gupta et al published in International Wound Journal, please visit: http://onlinelibrary.wiley.com/doi/10.1111/iwj.12452/epdf.

 

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.

 

For more information, contact:


Cheston Turbyfill
Acelity Corporate Communications
Email: cheston.turbyfill@acelity.com

 

Caleb Moore
Acelity Investor Relations
Email: caleb.moore@acelity.com


  • Share on Facebook.com
  • Share on Twitter
  • Besuchen Sie unsere YourTube Seite

Wichtige Mitteilung für Patienten

Rechtliches | Datenschutzrichtlinien | Kontaktieren Sie uns | Impressum


© 1998 – 2013 KCI Licensing, Inc. Alle Rechte vorbehalten.    DSL# 09-03-193.DE

Die Informationen auf dieser Website wurden ausschließlich zur Nutzung in Deutschland / KCI Medizinprodukte GmbH bereitgestellt. Diese Website enthält Informationen über Produkte, die möglicherweise nicht in allen Ländern verfügbar sind. Es ist außerdem möglich, dass sie von den zuständigen Behörden in bestimmten Ländern noch nicht oder nicht für bestimmte Indikationen zugelassen sind.